Editas Medicine Inc. (NASDAQ: EDIT) announced the pricing of a public offering of 55,555,556 shares of common stock and accompanying warrants at $2.25 per combined unit. The gene editing company expects to receive gross proceeds of approximately $125 million before underwriting fees and expenses.

Each warrant allows the purchase of one share at $3.50 and becomes exercisable immediately. The warrants expire either 30 days after the company announces Phase 1 clinical data for its EDIT-401 product candidate showing at least three patients with greater than 80% reduction in LDL-cholesterol compared to baseline, or three years from issuance, whichever occurs first.

If all warrants are exercised, Editas Medicine would receive additional gross proceeds of approximately $194.4 million before fees, bringing total potential proceeds to $319.4 million.

The offering is expected to close on May 27, 2026, subject to customary closing conditions. Cantor and Wells Fargo Securities are serving as joint book-running managers.

The securities are being offered under an effective shelf registration statement filed with the Securities and Exchange Commission. Editas Medicine develops gene editing medicines using CRISPR technology and holds exclusive licenses to Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines.